Uterine Fibroids Overview

Uterine Fibroids: Uterine fibroids are benign (not cancer) growths that develop from the muscle tissue of the uterus. Theyalso are called leiomyomas or myomas. The size, shape, and location of fibroids can vary greatly. They may be inside the uterus, on its outer surface or within its wall, or attached to it by a stem-like structure. A woman may have only one fibroid or many of varying sizes.

“Uterine Fibroids Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uterine Fibroids Market.

The Uterine Fibroids Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Uterine Fibroids Pipeline Report:

• Companies across the globe are diligently working toward developing novel Uterine Fibroids treatment therapies with a considerable amount of success over the years. Uterine Fibroids Key players such as – Tium Bio, Antev, Ogeda, Bayer HealthCare Pharmaceuticals, Repros Therapeutics Inc., AbbVie, Takeda, and others, are developing therapies for the Uterine Fibroids treatment 
• Uterine Fibroids Emerging therapies such as – TU2670, Teverelix trifluoroacetate, Fezolinetant, Vilaprisan, Telapristone Acetate, Elagolix, Relugolix, and others are expected to have a significant impact on the Uterine Fibroids market in the coming years.   
• In May 2021, The first once-daily medication for uterine fibroids-related heavy menstrual bleeding in premenopausal women, MYFEMBREE, has been approved by the US Food and Drug Administration (FDA), according to a joint statement from Myovant Sciences and Pfizer Inc.
• In February 2021, Positive findings from the Phase III LIBERTY 1 and LIBERTY 2 trials were announced by Pfizer and Myovant. Companies are evaluating a once-daily combination therapy of relugolix plus estradiol and norethindrone acetate in women with uterine fibroids.

Route of Administration

Uterine Fibroids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Molecule Type

Products have been categorized under various Molecule types, such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Uterine Fibroids Pipeline Therapeutics Assessment

• Uterine Fibroids Assessment by Product Type
• Uterine Fibroids By Stage and Product Type
• Uterine Fibroids Assessment by Route of Administration
• Uterine Fibroids By Stage and Route of Administration
• Uterine Fibroids Assessment by Molecule Type
• Uterine Fibroids by Stage and Molecule Type

DelveInsight’s Uterine Fibroids Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Uterine Fibroids Drugs Under Different Phases of Clinical Development Include:

• TU2670: Tium Bio
• Teverelix trifluoroacetate: Antev
• Fezolinetant: Ogeda
• Linzagolix: Kissei Pharmaceutical
• Relugolix: Myovant Sciences
• Vilaprisan : Bayer HealthCare Pharmaceuticals
• Telapristone Acetate: Repros Therapeutics Inc.
• Elagolix: AbbVie
• Relugolix: Takeda

Get a Free Sample PDF Report to know more about Uterine Fibroids Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/uterine-fibroids-pipeline-insight

Uterine Fibroids Pipeline Analysis:

The Uterine Fibroids pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Uterine Fibroids with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Fibroids Treatment.
• Uterine Fibroids key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uterine Fibroids Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uterine Fibroids market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Uterine Fibroids product details are provided in the report. Download the Uterine Fibroids pipeline report to learn more about the emerging Uterine Fibroids therapies

Uterine Fibroids Pipeline Market Drivers

• Increase in the number of patients suffering from Uterine fibroids
• Increasing awareness about the disease

Uterine Fibroids Pipeline Market Barriers

• Higher cost of research and development

Scope of Uterine Fibroids Pipeline Drug Insight    

• Coverage: Global
• Key Uterine Fibroids Companies: Tium Bio, Antev, Ogeda, Bayer HealthCare Pharmaceuticals, Repros Therapeutics Inc., AbbVie, Takeda, and others
• Key Uterine Fibroids Therapies: TU2670, Teverelix trifluoroacetate, Fezolinetant, Vilaprisan, Telapristone Acetate, Elagolix, Relugolix, and others
• Uterine Fibroids Therapeutic Assessment: Uterine Fibroids current marketed and Uterine Fibroids emerging therapies
• Uterine Fibroids Market Dynamics: Uterine Fibroids market drivers and Uterine Fibroids market barriers 

Request for Sample PDF Report for Uterine Fibroids Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Uterine Fibroids drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting